Form of words:
New Delhi: Fluvoxamine, an antidepressant used to treat major depressive disorders and obsessive-compulsive disorder (OCD), may reduce the need for hospitalization among high-risk Covid-19 patients, according to a new clinical study. According to the test results published. Lancet Global Health Publication.
NS Study TOGETHER was part of the trial, which aims to examine the efficacy of eight repurposing treatments for Covid-19 among high-risk adult patients who are not hospitalized.
The fluvoxamine portion of the trial began in January 2021. Researchers recruited adults in Brazil who were symptomatic, who had tested positive for Covid, had not been vaccinated, and had at least one criteria for high risk.
For the study, 741 participants were given 100 mg of fluvoxamine twice daily for 10 days and 756 participants received a placebo.
The participants were observed for 28 days. The researchers recorded how many patients spent more than six hours receiving physician treatment in a particular Covid-19 emergency setting, or hospitalization.
Of the 741 participants who received fluvoxamine, 79 required an extended stay of more than six hours in an emergency setting or hospitalization, compared with 119 of the 756 participants who received a placebo.
The results show that the use of fluvoxamine to treat high-risk outpatients with early-diagnosed covid reduces the need for prolonged observation in an emergency setting or hospital compared to a control group that received a placebo. was received.
“Recent vaccination developments and campaigns have proven effective and important in reducing the number of new symptomatic cases, hospitalizations and deaths due to COVID-19. However, COVID-19 still poses a risk to individuals in countries with fewer resources and limited access to vaccinations,” said Edward Mills of McMaster University in Canada, co-principal investigator on the trial.
Mills said, “It is therefore very important to identify affordable, widely available and effective treatments against COVID-19, and to repurpose existing drugs that are widely available and have well-understood safety profiles.” are of particular interest.”
anti-inflammatory properties
Fluvoxamine is currently used to treat mental health conditions such as depression and obsessive-compulsive disorder. Due to its anti-inflammatory properties, it was selected for study as a potential treatment for covid.
“Fluvoxamine may reduce the production of inflammatory molecules called cytokines that may be triggered by SARS-CoV-2 infection,” study co-author Angela Reyerson, associate professor of psychiatry at Washington University in St. Louis, said in a statement. ”
“Our results are consistent with those of earlier, smaller trials. Given fluvoxamine’s safety, tolerability, ease of use, low cost, and wide availability, these findings are supported in an analysis of national and international guidelines on the clinical management of COVID-19. could have significant implications,” Gilmour Reis, co-principal investigator, based in Belo Horizonte, Brazil, said in the statement.
(Edited by Paramita Ghosh)
Read also: India receives at least 17 samples of Covid type AY.4.2, leading to thousands of cases in UK
subscribe our channel youtube And Wire
Why is the news media in crisis and how can you fix it?
India needs independent, unbiased, non-hyphenated and questionable journalism even more as it is facing many crises.
But the news media itself is in trouble. There have been brutal layoffs and pay-cuts. The best of journalism are shrinking, yielding to raw prime-time spectacle.
ThePrint has the best young journalists, columnists and editors to work for it. Smart and thinking people like you will have to pay a price to maintain this quality of journalism. Whether you live in India or abroad, you can Here.